Research ArticleClinical Investigation
An External, Independent Validation of an O-(2-[18F]Fluoroethyl)-l-Tyrosine PET Automatic Segmentation Network on a Single-Center, Prospective Dataset of Patients with Glioblastoma
Nathaniel Barry, Jake Kendrick, Pejman Rowshanfarzad, Ghulam Mubashar Hassan, Roslyn J. Francis, Nicholas Bucknell, Eng-Siew Koh, Andrew M. Scott, Martin A. Ebert, Robin Gutsche, Keith George Ciantar, Norbert Galldiks, Karl-Josef Langen and Philipp Lohmann
Journal of Nuclear Medicine April 2025, jnumed.124.268925; DOI: https://doi.org/10.2967/jnumed.124.268925
Nathaniel Barry
1School of Physics, Mathematics and Computing, University of Western Australia, Crawley, Western Australia, Australia;
2Centre for Advanced Technologies in Cancer Research, Perth, Western Australia, Australia;
Jake Kendrick
1School of Physics, Mathematics and Computing, University of Western Australia, Crawley, Western Australia, Australia;
2Centre for Advanced Technologies in Cancer Research, Perth, Western Australia, Australia;
3Australian Centre for Quantitative Imaging, Medical School, University of Western Australia, Crawley, Western Australia, Australia;
Pejman Rowshanfarzad
1School of Physics, Mathematics and Computing, University of Western Australia, Crawley, Western Australia, Australia;
2Centre for Advanced Technologies in Cancer Research, Perth, Western Australia, Australia;
Ghulam Mubashar Hassan
1School of Physics, Mathematics and Computing, University of Western Australia, Crawley, Western Australia, Australia;
3Australian Centre for Quantitative Imaging, Medical School, University of Western Australia, Crawley, Western Australia, Australia;
Roslyn J. Francis
3Australian Centre for Quantitative Imaging, Medical School, University of Western Australia, Crawley, Western Australia, Australia;
4Department of Nuclear Medicine, Royal Brisbane and Women’s Hospital, Herston, Queensland, Australia;
Nicholas Bucknell
5Department of Radiation Oncology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia;
Eng-Siew Koh
6Department of Radiation Oncology, Liverpool and Macarthur Cancer Therapy Centres, Liverpool, New South Wales, Australia;
7South Western Sydney Clinical School, University of New South Wales, Warwick Farm, New South Wales, Australia;
Andrew M. Scott
8Department of Molecular Imaging and Therapy, Austin Health, and University of Melbourne, Melbourne, Victoria, Australia;
9Olivia Newton-John Cancer Research Institute, and School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia;
Martin A. Ebert
1School of Physics, Mathematics and Computing, University of Western Australia, Crawley, Western Australia, Australia;
2Centre for Advanced Technologies in Cancer Research, Perth, Western Australia, Australia;
3Australian Centre for Quantitative Imaging, Medical School, University of Western Australia, Crawley, Western Australia, Australia;
5Department of Radiation Oncology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia;
Robin Gutsche
10Institute of Neuroscience and Medicine, Forschungszentrum Juelich GmbH, Juelich, Germany;
Keith George Ciantar
10Institute of Neuroscience and Medicine, Forschungszentrum Juelich GmbH, Juelich, Germany;
11Institute of Imaging and Computer Vision, RWTH Aachen University, Aachen, Germany;
Norbert Galldiks
10Institute of Neuroscience and Medicine, Forschungszentrum Juelich GmbH, Juelich, Germany;
12Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany;
13Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), Germany; and
Karl-Josef Langen
10Institute of Neuroscience and Medicine, Forschungszentrum Juelich GmbH, Juelich, Germany;
13Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), Germany; and
14Department of Nuclear Medicine, University Hospital RWTH Aachen, Aachen, Germany
Philipp Lohmann
10Institute of Neuroscience and Medicine, Forschungszentrum Juelich GmbH, Juelich, Germany;
14Department of Nuclear Medicine, University Hospital RWTH Aachen, Aachen, Germany

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
SNMMI members
Login to the site using your SNMMI member credentials
Individuals
Login as an individual user
In this issue
Journal of Nuclear Medicine
Vol. 66, Issue 4
April 1, 2025
An External, Independent Validation of an O-(2-[18F]Fluoroethyl)-l-Tyrosine PET Automatic Segmentation Network on a Single-Center, Prospective Dataset of Patients with Glioblastoma
Nathaniel Barry, Jake Kendrick, Pejman Rowshanfarzad, Ghulam Mubashar Hassan, Roslyn J. Francis, Nicholas Bucknell, Eng-Siew Koh, Andrew M. Scott, Martin A. Ebert, Robin Gutsche, Keith George Ciantar, Norbert Galldiks, Karl-Josef Langen, Philipp Lohmann
Journal of Nuclear Medicine Apr 2025, jnumed.124.268925; DOI: 10.2967/jnumed.124.268925
An External, Independent Validation of an O-(2-[18F]Fluoroethyl)-l-Tyrosine PET Automatic Segmentation Network on a Single-Center, Prospective Dataset of Patients with Glioblastoma
Nathaniel Barry, Jake Kendrick, Pejman Rowshanfarzad, Ghulam Mubashar Hassan, Roslyn J. Francis, Nicholas Bucknell, Eng-Siew Koh, Andrew M. Scott, Martin A. Ebert, Robin Gutsche, Keith George Ciantar, Norbert Galldiks, Karl-Josef Langen, Philipp Lohmann
Journal of Nuclear Medicine Apr 2025, jnumed.124.268925; DOI: 10.2967/jnumed.124.268925
Jump to section
Related Articles
Cited By...
- No citing articles found.